Document Server@UHasselt >
Research publications >
Please use this identifier to cite or link to this item:
|Title: ||Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids|
|Authors: ||van Staa, T.|
|Issue Date: ||2007|
|Citation: ||RHEUMATOLOGY, 46(3). p. 460-466|
|Abstract: ||Objectives. There are few data on the cost-effectiveness of bisphosphonates with oral glucocorticoids (GCs). An individual patient-based pharmaco-economic model was developed.
Methods. Data were obtained from a cohort of oral GC users aged 40+ (n = 190 000) in the UK General Practice Research Database. Individualized fracture and mortality risks were calculated specific for age, sex, daily and cumulative GC dose, indication and other clinical risk factors. UK costs of medication and direct costs of fracture were obtained from National Institute for Clinical Excellence and used to estimate costs per quality-adjusted life-year (QALY) gained and fracture prevented for bisphosphonates in patients treated for 5 yrs with GCs.
Results. With the use of 5 mg GCs daily, the cost per one QALY gained with bisphosphonates was 41k UK pounds (95% confidence intervals 22–72k) in women aged <60 [men £40k (29–54k)], £17k (13–24k) in women aged 60–79 [men £43k (31–60k)], £5k (3–6k) in women aged 80+ [men £35k (25–46k)]. With 15 mg GC, these figures were £17k (14–21k), £13k (10–16k) and £15k (9–26k) in women and £22k (17–26k), £34 (23–53k) and £33k (27–42k) in men, respectively. When stratifying by overall fracture risk and life expectancy at the start of GC therapy, cost per QALY increased with decreasing life expectancy. Patients with rheumatoid arthritis had comparatively better cost-effectiveness, given higher fracture risk and better life expectancy.
Conclusions. The cost-effectiveness of bisphosphonates varied substantially. Bisphosphonates can be considered cost-effective in patients with higher fracture risks, such as elderly patients (with a life expectancy over 5 yrs), and younger patients with a fracture history, low body mass index, rheumatoid arthritis or using high GC doses.|
|ISI #: ||000244427500018|
|Type: ||Journal Contribution|
|Validation: ||ecoom, 2008|
|Appears in Collections: ||Research publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.